Compare AbbVie Inc (ABBV) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Nomura Holdings Inc — how do they compare? AbbVie Inc trades at $247.54 (market cap $441.94B), while Nomura Holdings Inc trades at $9.91 (market cap $28.46B). The key difference: AbbVie Inc is far larger — about 15.5× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.31%). Which is the better fit depends on your goals.
| ABBV | NMR | |
|---|---|---|
Market Cap | $441.94B | $28.46B |
Sector | Health | Financials |
52-Week High | $263.58 | $10.04 |
52-Week Low | $197.38 | $6.73 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Nomura Holdings (NMR) trades at $9.82, down 1.31% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company reported strong revenue growth, with 2025 revenue reaching $1.66 trillion and net income of $340.74 billion, yielding a robust net margin of 20.4%. Recent earnings show a mix of beats and misses, with Q2 2026 EPS beating expectations. Analyst sentiment is mixed, with a 'Hold' consensus but positive momentum coverage in financial media.
The outlook for NMR is supported by fundamental strength in profitability and revenue expansion, though cash flow volatility and rising debt-to-asset ratios pose risks. The stock presents a value opportunity with a P/E of 11.59, but investors should weigh consistent earnings performance against macroeconomic and sector-specific headwinds affecting financial stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
